IMMUNOSCINTIGRAPHY IN MALIGNANT-MELANOMA - A 5-YEAR CLINICAL-EXPERIENCE

被引：16

作者：

FEGGI, L

INDELLI, M

PANSINI, GC

SANTINI, A

PRANDINI, N

VIRGILI, AR

机构：

[1] Department of Medical Oncology, Ospedale S. Anna-Ferrara

[2] Department of Dermatology, University of Ferrara, Ferrara

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1993年 / 14卷 / 02期

关键词：

D O I：

10.1097/00006231-199302000-00013

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Immunoscintigraphy (IS) with Tc-99(m)-labelled anti-melanoma monoclonal antibody F(ab')2 fragments was performed in 135 melanoma patients, 64 males and 71 females, aged 19-82 years (mean 52.3 years) between December 1987 and December 1991. The first group of IS was performed in 50 patients before surgery to assess optimal management: seven true positive and one true negative were obtained in ocular and visceral melanomas, while in cutaneous MM sensitivity, specificity and accuracy in assessing lymph node involvement were, respectively, 61.5, 93.3 and 83.7%. The second group of 128 IS is relative to 85 patients in follow-up: excluding 13 cases with known metastatic disease and 12 inconclusive tests, sensitivity, specificity and accuracy were, respectively, 83.3, 98.8 and 96.1%. Immunoscintigraphy is free of side effects even after repeated administrations and is a useful adjunct to standard diagnostic techniques as a basis for treatment decisions.

引用

页码：145 / 148

页数：4

共 21 条

[1]

Koehler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, pp. 495-497, (1975)

[2]

Pressmann D., Korngold L., The in 1’ivo localizing of anti- Wagner osteogenic sarcoma antibodies, Cancer, 6, pp. 619-623, (1953)

[3]

Matzku S., Kirchgessner H., Et al., Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA, J Nucl Med, 30, pp. 390-397, (1989)

[4]

Natali P.G., Wilson B.S., Et al., Tissue distribution, molecular profile and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465. 12S to human melanoma cells, Cancer Res, 42, pp. 583-589, (1982)

[5]

Ferrone S., Giacomini P., Et al., A human high molecular weight-melanoma associated antigen (HMW-MAA) defined by monoclonal antibodies. First International Meeting on Boron Neutron Capture, MIT Boston, pp. 174-183, (1983)

[6]

Larson S.M., Clinical radioimmunodetection, 1978-1988: Overview and suggestions for standardization of clinical trials, Cancer Res, 50, (1991)

[7]

Murray J.L., Lamki L.M., Rosenblum M.G., Radioimmuno- imaging of malignant melanoma with monoclonal antibodies, Cancer Treat Res, 43, pp. 123-153, (1988)

[8]

Schaling D.F., Van Der pol J.O.P., Jager M.J., Et al., Radioim- munoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: A comparison of the clinical and immunohis- tochemical results, Br J Ophthalmol, 74, pp. 538-541, (1990)

[9]

Siccardi A.G., Buraggi G.L., Natali P.G., Et al., European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group, Eur J Nucl Med, 16, pp. 317-323, (1990)

[10]

Larson S.M., Radioimmunology

← 1 2 3 →